Pan-PPAR Agonist Therapy for Tauopathy Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Huntington's disease and tauopathies, including Alzheimer's, lack effective therapeutic methods to delay symptom onset or progression.
Innovation Solution
Administration of a pan-PPAR agonist, specifically bezafibrate, which activates PPAR receptors to improve mitochondrial biogenesis, reduce oxidative stress, and inhibit inflammatory pathways, thereby providing neuroprotection and improving behavioral and neuropathological outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurodegenerative diseases are used, then disease progression is managed, but effective therapeutic methods to delay symptom onset or progression are lacking
Solution Approach 1:
The patent changes the pharmacological parameter by using pan-PPAR agonists that simultaneously activate multiple PPAR isoforms (α, β/δ, and γ) rather than targeting a single isoform. This multi-target approach fundamentally alters the therapeutic mechanism to address multiple pathological pathways in neurodegenerative diseases, including mitochondrial dysfunction, oxidative stress, and neuroinflammation, thereby improving therapeutic effectiveness and delaying symptom progression
Solution Approach 2:
The pan-PPAR agonist formulation provides multi-functionality by simultaneously engaging three different PPAR isoforms, each targeting different aspects of disease pathology. PPARα activation addresses mitochondrial function and lipid metabolism, PPARβ/δ activation addresses neuroprotection and metabolism, and PPARγ activation addresses inflammation and insulin sensitivity. This universal approach covers multiple disease mechanisms within a single therapeutic agent
2Reliability
If pan-PPAR agonists are administered, then neuroprotection and behavioral improvement are achieved, but the complexity of targeting multiple PPAR isoforms increases
Solution Approach 1:
The patent merges the functions of three separate PPAR isoform agonists into a single pan-PPAR agonist molecule. Instead of administering multiple drugs to target PPARα, PPARβ/δ, and PPARγ separately, the invention uses one compound that can activate all three isoforms simultaneously, thereby simplifying the therapeutic regimen while maintaining comprehensive neuroprotective effects across multiple pathological pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Bezafibrate treatment significantly improves behavioral phenotypes, extends survival, reduces neuropathological features, and enhances mitochondrial density in Huntington's disease models, while also reducing tau hyperphosphorylation and inflammation in tauopathy models, offering a promising therapeutic approach for these diseases.
Implementation Method 1
activates PPAR receptors to improve mitochondrial biogenesis
Implementation Method 2
reduce oxidative stress
Implementation Method 3
inhibit inflammatory pathways
Implementation Method 4
reducing tauhyperphosphorylation
Data Source
AI summary
The present invention provides a therapeutic treatment for a neurodegenerative disease with a pan-PPAR agonist, such as bezafibrate. In particular, the present invention provides that pan-PPAR agonists enhance PPAR related responses in both the central nervous system and peripheral tissues in Huntington's Disease (HD) and tauopathy. Therapeutic compositions comprising one or more pan-PPAR agonist(s), and kit thereof, for treating a neurodegenerative disease or disorder are also provided.